Early-stage clinical trials can be a bottleneck in drug development leading to uncertainty and inefficiency. ACRO is actively working to identify regulatory, structural, and policy barriers and has developed a set of 5 actionable policy recommendations intended to strengthen U.S. leadership in early-stage drug development research.